General Information of Drug (ID: DMTXPSB)

Drug Name
DB-200 Drug Info
Synonyms DB-200 series (topical, psoriasis); CPT-1 inhibitor (topical, psoriasis), DARA; DB-200 series (topical, psoriasis), DARA BioSciences
Indication
Disease Entry ICD 11 Status REF
Psoriasis vulgaris EA90 Terminated [1]
Cross-matching ID
TTD Drug ID
DMTXPSB

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Levacecarnine hci DMJBOCR Cognitive impairment 6D71 Approved [3]
Perhexiline DMINO7Z Angina pectoris BA40 Approved [4]
SDZ-CPI-975 DM70MJQ Diabetic complication 5A2Y Discontinued in Phase 1 [5]
Etomoxir DM3BHN1 Heart failure BD10-BD13 Terminated [6]
C75 DMHGX1N Obesity 5B81 Investigative [7]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Carnitine O-palmitoyltransferase I (CPT1B) TTDL0NY CPT1B_HUMAN Inhibitor [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026687)
2 Comparison of the effects of carnitine palmitoyltransferase-1 and -2 inhibitors on rat heart hypertrophy. Cardioscience. 1994 Sep;5(3):193-7.
3 Central ghrelin regulates peripheral lipid metabolism in a growth hormone-independent fashion. Endocrinology. 2009 Oct;150(10):4562-74.
4 Perhexiline. Cardiovasc Drug Rev. 2007 Spring;25(1):76-97.
5 Hypoglycemic effects of a novel fatty acid oxidation inhibitor in rats and monkeys. Am J Physiol. 1998 Feb;274(2 Pt 2):R524-8.
6 Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine. Circ Res. 1988 Dec;63(6):1036-43.
7 C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity. Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9498-502.